434 related articles for article (PubMed ID: 11436584)
21. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
Shahian M; Alborzi A
Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
[TBL] [Abstract][Full Text] [Related]
22. Use of meglumine antimoniate in canine leishmaniasis.
Lamothe J
Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
[No Abstract] [Full Text] [Related]
23. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
25. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
26. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
27. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
Soto J; Toledo J; Vega J; Berman J
Am J Trop Med Hyg; 2005 Apr; 72(4):421-2. PubMed ID: 15827279
[TBL] [Abstract][Full Text] [Related]
28. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
[TBL] [Abstract][Full Text] [Related]
29. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
30. Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate.
Rodrigues AM; Hueb M; Nery AF; Fontes CJ
Acta Trop; 2007 May; 102(2):113-8. PubMed ID: 17555699
[TBL] [Abstract][Full Text] [Related]
31. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
32. Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
Rashid BN; Tabassum S; Ullah Rao MS; Masood S; Abbas MM; Mumtaz MJ
J Coll Physicians Surg Pak; 2010 Jul; 20(7):496. PubMed ID: 20642959
[No Abstract] [Full Text] [Related]
33. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM
Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234
[TBL] [Abstract][Full Text] [Related]
34. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
35. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
36. Glucantime-resistant visceral leishmaniasis in immunocompromised patients.
Verdejo J; Alvar J; Polo RM; González-Lahoz JM
Am J Med; 1988 Jul; 85(1):128. PubMed ID: 3389377
[No Abstract] [Full Text] [Related]
37. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
Salmanpour R; Razmavar MR; Abtahi N
Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529
[No Abstract] [Full Text] [Related]
38. [Agranulocytosis caused by glucantime (N-methylglucamine antimoniate) during treatment of kala-azar].
Gutiérrez Rodero F; Moya Jeromini I; Ortiz de la Tabla Ducasse V; Pozuelo González A
Med Clin (Barc); 1985 May; 84(20):840. PubMed ID: 4033266
[No Abstract] [Full Text] [Related]
39. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
40. Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis.
Zanoni LZ; Brustoloni YM; Melnikov P; Cônsolo CE
Biol Trace Elem Res; 2009 Dec; 132(1-3):35-40. PubMed ID: 19424667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
